Literature DB >> 25645630

The anti-ictogenic effects of levetiracetam are mirrored by interictal spiking and high-frequency oscillation changes in a model of temporal lobe epilepsy.

Maxime Lévesque1, Charles Behr1, Massimo Avoli2.   

Abstract

PURPOSE: Mesial temporal lobe epilepsy (MTLE) is the most prevalent type of partial epileptic disorders. In this study, we have analyzed the impact of levetiracetam (LEV) in the pilocarpine model of MTLE.
METHODS: Sprague-Dawley rats (n=19) were injected with pilocarpine (380 mg/kg, i.p.) to induce a status epilepticus. Twelve animals were used as controls and seven were treated with LEV. They were implanted with bipolar electrodes in the CA3 subfield of the hippocampus, entorhinal cortex (EC), dentate gyrus (DG) and subiculum and EEG-video monitored continuously from day 4 to day 14 after SE.
RESULTS: Only 29% of LEV-treated animals had seizures compared to all controls following a latent period that was similar in duration. Seizure rates were lower in LEV-treated animals. In LEV-treated animals without seizures, lower interictal spike rates were found in all regions compared to controls. Analysis of interictal high-frequency oscillations (HFO s) revealed that LEV-treated animals without seizures had lower rates of interictal spikes with ripples (80-200 Hz) in CA3, EC and subiculum (p<0.01), whereas rates of interictal spikes with fast ripples (250-500 Hz) were significantly lower in CA3 and subiculum, compared to controls.
CONCLUSION: Our findings indicate that the anti-ictogenic properties of LEV are mirrored by decreases of interictal spike rate in temporal lobe regions, and are accompanied by subregion-specific decreases of HFO occurrence in CA3 and subiculum. Overall, this evidence suggest that LEV may inhibit neural network activity in regions that are known to play important roles in MTLE.
Copyright © 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  High-frequency oscillations; Interictal spikes; Levetiracetam; Pilocarpine; Seizures

Mesh:

Substances:

Year:  2014        PMID: 25645630      PMCID: PMC4880465          DOI: 10.1016/j.seizure.2014.11.008

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  42 in total

Review 1.  Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders.

Authors:  Massimo Mantegazza; Giulia Curia; Giuseppe Biagini; David S Ragsdale; Massimo Avoli
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

2.  A comparison of the efficacy of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy.

Authors:  H C Doheny; M A Whittington; J G R Jefferys; P N Patsalos
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

3.  Levetiracetam suppresses development of spontaneous EEG seizures and aberrant neurogenesis following kainate-induced status epilepticus.

Authors:  Yuki Sugaya; Eiichi Maru; Koutaro Kudo; Tamotsu Shibasaki; Nobumasa Kato
Journal:  Brain Res       Date:  2010-06-30       Impact factor: 3.252

4.  High-frequency electroencephalographic oscillations correlate with outcome of epilepsy surgery.

Authors:  Julia Jacobs; Maeike Zijlmans; Rina Zelmann; Claude-Edouard Chatillon; Jeffrey Hall; André Olivier; François Dubeau; Jean Gotman
Journal:  Ann Neurol       Date:  2010-02       Impact factor: 10.422

5.  Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy.

Authors:  W Löscher; D Hönack; C Rundfeldt
Journal:  J Pharmacol Exp Ther       Date:  1998-02       Impact factor: 4.030

6.  Glutamatergic pre-ictal discharges emerge at the transition to seizure in human epilepsy.

Authors:  Gilles Huberfeld; Liset Menendez de la Prida; Johan Pallud; Ivan Cohen; Michel Le Van Quyen; Claude Adam; Stéphane Clemenceau; Michel Baulac; Richard Miles
Journal:  Nat Neurosci       Date:  2011-04-03       Impact factor: 24.884

Review 7.  Levetiracetam: a review of its use in epilepsy.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2011-03-05       Impact factor: 9.546

8.  The role of epileptic activity in hippocampal and "remote" cerebral lesions induced by kainic acid.

Authors:  Y Ben-Ari; E Tremblay; O P Ottersen; B S Meldrum
Journal:  Brain Res       Date:  1980-06-02       Impact factor: 3.252

9.  Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy.

Authors:  Henrik Klitgaard; Alain Matagne; Renee Grimee; Jocelyne Vanneste-Goemaere; Doru-Georg Margineanu
Journal:  Seizure       Date:  2003-03       Impact factor: 3.184

10.  Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats.

Authors:  Doru-Georg Margineanu; Alain Matagne; Rafal M Kaminski; Henrik Klitgaard
Journal:  Brain Res Bull       Date:  2008-08-21       Impact factor: 4.077

View more
  10 in total

Review 1.  Update on the mechanisms and roles of high-frequency oscillations in seizures and epileptic disorders.

Authors:  Premysl Jiruska; Catalina Alvarado-Rojas; Catherine A Schevon; Richard Staba; William Stacey; Fabrice Wendling; Massimo Avoli
Journal:  Epilepsia       Date:  2017-07-06       Impact factor: 5.864

Review 2.  Levetiracetam Mechanisms of Action: From Molecules to Systems.

Authors:  Itzel Jatziri Contreras-García; Noemí Cárdenas-Rodríguez; Antonio Romo-Mancillas; Cindy Bandala; Sergio R Zamudio; Saúl Gómez-Manzo; Beatriz Hernández-Ochoa; Julieta Griselda Mendoza-Torreblanca; Luz Adriana Pichardo-Macías
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-13

3.  Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein.

Authors:  Kouji Fukuyama; Motohiro Okada
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

Review 4.  Animal models of temporal lobe epilepsy following systemic chemoconvulsant administration.

Authors:  Maxime Lévesque; Massimo Avoli; Christophe Bernard
Journal:  J Neurosci Methods       Date:  2015-03-10       Impact factor: 2.390

5.  Phase-amplitude coupling and epileptogenesis in an animal model of mesial temporal lobe epilepsy.

Authors:  Soheila Samiee; Maxime Lévesque; Massimo Avoli; Sylvain Baillet
Journal:  Neurobiol Dis       Date:  2018-02-24       Impact factor: 5.996

6.  Anti-Epileptic Drug Combination Efficacy in an In Vitro Seizure Model - Phenytoin and Valproate, Lamotrigine and Valproate.

Authors:  Kim Det Taing; Terence J O'Brien; David A Williams; Chris R French
Journal:  PLoS One       Date:  2017-01-11       Impact factor: 3.240

7.  Lacosamide and Levetiracetam Have No Effect on Sharp-Wave Ripple Rate.

Authors:  Jan Kudlacek; Jan Chvojka; Antonin Posusta; Lubica Kovacova; Seung Bong Hong; Shennan Weiss; Kamila Volna; Petr Marusic; Jakub Otahal; Premysl Jiruska
Journal:  Front Neurol       Date:  2017-12-21       Impact factor: 4.003

Review 8.  Neurosteroids and Focal Epileptic Disorders.

Authors:  Maxime Lévesque; Giuseppe Biagini; Massimo Avoli
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

9.  Levetiracetam Reduced the Basal Excitability of the Dentate Gyrus without Restoring Impaired Synaptic Plasticity in Rats with Temporal Lobe Epilepsy.

Authors:  Guillermo González-H; Itzel Jatziri Contreras-García; Karla Sánchez-Huerta; Claudio M T Queiroz; Luis Ricardo Gallardo Gudiño; Julieta G Mendoza-Torreblanca; Sergio R Zamudio
Journal:  Brain Sci       Date:  2020-09-11

10.  HFO to Measure Seizure Propensity and Improve Prognostication in Patients With Epilepsy.

Authors:  Julia Jacobs; Maeike Zijlmans
Journal:  Epilepsy Curr       Date:  2020-10-20       Impact factor: 7.500

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.